Table 2.
Patient characteristics
Characteristics | No. of patients (%) |
---|---|
Original study | |
Pazopanib TDM [17] | 13 (14) |
Phase I with docetaxel [1] | 40 (43) |
Phase I with ifosfamide [2] | 41 (44) |
Sex | |
Male | 67 (71) |
Female | 27 (29) |
Age, y, median (IQR) | 57 (48–64) |
Pazopanib starting dose (mg QD) | |
200 | 18 (19) |
400 | 38 (40) |
600 800 |
3 (3) 20 (21) |
1000 | 15 (16) |
Ethnicity | |
Caucasian | 91 (97) |
Asian | 2 (2) |
Black | 1 (1) |
IQR inter-quartile range, QD quoque dies (once daily), TDM therapeutic drug monitoring